Immunotherapy and Cancer Therapeutics: A Rich Partnership

Gang Chen, Elizabeth Jaffee, Leisha A. Emens

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition
PublisherElsevier Inc.
Pages415-432
Number of pages18
ISBN (Print)9780123942968
DOIs
StatePublished - Jul 2013

Fingerprint

Immunotherapy
Drug Therapy
Neoplasms
Therapeutics
Radiation Effects
Standard of Care
Immune System
Radiotherapy
Monoclonal Antibodies
Growth

Keywords

  • Cancer therapeutics
  • Chemotherapy
  • Immunotherapy
  • Monoclonal antibodies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Chen, G., Jaffee, E., & Emens, L. A. (2013). Immunotherapy and Cancer Therapeutics: A Rich Partnership. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition (pp. 415-432). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394296-8.00025-7

Immunotherapy and Cancer Therapeutics : A Rich Partnership. / Chen, Gang; Jaffee, Elizabeth; Emens, Leisha A.

Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. p. 415-432.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chen, G, Jaffee, E & Emens, LA 2013, Immunotherapy and Cancer Therapeutics: A Rich Partnership. in Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., pp. 415-432. https://doi.org/10.1016/B978-0-12-394296-8.00025-7
Chen G, Jaffee E, Emens LA. Immunotherapy and Cancer Therapeutics: A Rich Partnership. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc. 2013. p. 415-432 https://doi.org/10.1016/B978-0-12-394296-8.00025-7
Chen, Gang ; Jaffee, Elizabeth ; Emens, Leisha A. / Immunotherapy and Cancer Therapeutics : A Rich Partnership. Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. pp. 415-432
@inbook{c4d7661d3bcf4663b3950452575f64a3,
title = "Immunotherapy and Cancer Therapeutics: A Rich Partnership",
abstract = "Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.",
keywords = "Cancer therapeutics, Chemotherapy, Immunotherapy, Monoclonal antibodies, Tyrosine kinase inhibitors",
author = "Gang Chen and Elizabeth Jaffee and Emens, {Leisha A.}",
year = "2013",
month = "7",
doi = "10.1016/B978-0-12-394296-8.00025-7",
language = "English (US)",
isbn = "9780123942968",
pages = "415--432",
booktitle = "Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Immunotherapy and Cancer Therapeutics

T2 - A Rich Partnership

AU - Chen, Gang

AU - Jaffee, Elizabeth

AU - Emens, Leisha A.

PY - 2013/7

Y1 - 2013/7

N2 - Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.

AB - Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.

KW - Cancer therapeutics

KW - Chemotherapy

KW - Immunotherapy

KW - Monoclonal antibodies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84902216173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902216173&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394296-8.00025-7

DO - 10.1016/B978-0-12-394296-8.00025-7

M3 - Chapter

AN - SCOPUS:84902216173

SN - 9780123942968

SP - 415

EP - 432

BT - Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition

PB - Elsevier Inc.

ER -